[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

May 2024 | 130 pages | ID: I0198EBE69D2EN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major ischemia markets are expected to exhibit a CAGR of 3.91% during 2024-2034.

The ischemia market has been comprehensively analyzed in IMARC's new report titled "Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ischemia refers to a medical condition characterized by inadequate blood flow to a specific organ or tissue in the body. As a result, there's a decreased oxygen and nutrient supply to the affected area, causing irreversible tissue damage or cell death. Ischemia can occur in various parts of the body, including the heart, brain, limbs, and other vital organs. Some general symptoms of this disease are chest pain or angina, shortness of breath, fatigue, abdominal pain, weakness, numbness, changes in skin color or temperature, delayed wound healing, the development of ulcers, etc. The diagnosis of the ailment typically involves a combination of medical history evaluation, clinical feature assessment, physical examination, and diagnostic tests. Various imaging techniques, such as cardiac computed tomography and magnetic resonance imaging, are further utilized to assess blood flow and identify areas of reduced perfusion in individuals suffering from ischemia. In addition to this, the healthcare provider may recommend an electrocardiogram test to measure the electrical activity of the heart and rule out other health conditions.

The increasing cases of atherosclerosis, which can result in the buildup of fatty plaques and narrowing of the blood vessels, are primarily driving the ischemia market. In addition to this, the rising prevalence of thrombosis or embolism that disrupts the blood flow and deprives the affected tissues of oxygen and nutrients due to the formation of clots is also creating a positive outlook for the market. Moreover, the widespread demand for effective drugs, including antiplatelets, anticoagulants, vasodilators, etc., since they help to widen blood vessels and reduce disease symptoms, is further bolstering the market growth. Apart from this, the inflating application of lifestyle modifications, which involve quitting smoking, adopting a healthy diet low in saturated fats and cholesterol, maintaining a balanced weight, and practicing regular exercise, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hyperbaric oxygen therapy for the treatment of the ailment on account of its several advantages, like reduced cell damage, stimulated growth of new blood vessels, and improved oxygenation of hypoxic tissues, is expected to drive the ischemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the ischemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ischemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ischemia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ischemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ischemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current ischemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the ischemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the ischemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the ischemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of ischemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of ischemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of ischemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with ischemia across the seven major markets?
What is the size of the ischemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of ischemia?
What will be the growth rate of patients across the seven major markets?

Ischemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for ischemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ischemia market?
What are the key regulatory events related to the ischemia market?
What is the structure of clinical trial landscape by status related to the ischemia market?
What is the structure of clinical trial landscape by phase related to the ischemia market?
What is the structure of clinical trial landscape by route of administration related to the ischemia market?
?1 Preface

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ISCHEMIA - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 ISCHEMIA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 ISCHEMIA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (2018-2023)
  7.2.2 Epidemiology Forecast (2024-2034)
  7.2.3 Epidemiology by Age (2018-2034)
  7.2.4 Epidemiology by Gender (2018-2034)
  7.2.5 Diagnosed Cases (2018-2034)
  7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (2018-2023)
  7.3.2 Epidemiology Forecast (2024-2034)
  7.3.3 Epidemiology by Age (2018-2034)
  7.3.4 Epidemiology by Gender (2018-2034)
  7.3.5 Diagnosed Cases (2018-2034)
  7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (2018-2023)
  7.4.2 Epidemiology Forecast (2024-2034)
  7.4.3 Epidemiology by Age (2018-2034)
  7.4.4 Epidemiology by Gender (2018-2034)
  7.4.5 Diagnosed Cases (2018-2034)
  7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (2018-2023)
  7.5.2 Epidemiology Forecast (2024-2034)
  7.5.3 Epidemiology by Age (2018-2034)
  7.5.4 Epidemiology by Gender (2018-2034)
  7.5.5 Diagnosed Cases (2018-2034)
  7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (2018-2023)
  7.6.2 Epidemiology Forecast (2024-2034)
  7.6.3 Epidemiology by Age (2018-2034)
  7.6.4 Epidemiology by Gender (2018-2034)
  7.6.5 Diagnosed Cases (2018-2034)
  7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (2018-2023)
  7.7.2 Epidemiology Forecast (2024-2034)
  7.7.3 Epidemiology by Age (2018-2034)
  7.7.4 Epidemiology by Gender (2018-2034)
  7.7.5 Diagnosed Cases (2018-2034)
  7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (2018-2023)
  7.8.2 Epidemiology Forecast (2024-2034)
  7.8.3 Epidemiology by Age (2018-2034)
  7.8.4 Epidemiology by Gender (2018-2034)
  7.8.5 Diagnosed Cases (2018-2034)
  7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (2018-2023)
  7.9.2 Epidemiology Forecast (2024-2034)
  7.9.3 Epidemiology by Age (2018-2034)
  7.9.4 Epidemiology by Gender (2018-2034)
  7.9.5 Diagnosed Cases (2018-2034)
  7.9.6 Patient Pool/Treated Cases (2018-2034)

8 ISCHEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 ISCHEMIA - UNMET NEEDS

10 ISCHEMIA - KEY ENDPOINTS OF TREATMENT

11 ISCHEMIA - MARKETED PRODUCTS

11.1 List of Ischemia Marketed Drugs Across the Top 7 Markets
  11.1.1 Norvasc Amlodipine besylate) - Pfizer
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
  11.1.2 Zocor (Simvastatin) - Merck & Co
    11.1.2.1 Drug Overview
    11.1.2.2 Mechanism of Action
    11.1.2.3 Regulatory Status
    11.1.2.4 Clinical Trial Results
    11.1.2.5 Sales Across Major Markets
  11.1.3 Crestor (Rosuvastatin) - AstraZeneca
    11.1.3.1 Drug Overview
    11.1.3.2 Mechanism of Action
    11.1.3.3 Regulatory Status
    11.1.3.4 Clinical Trial Results
    11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 ISCHEMIA - PIPELINE DRUGS

12.1 List of Ischemia Pipeline Drugs Across the Top 7 Markets
  12.1.1 Ezetimibe - Merck/Schering-Plough Pharmaceuticals
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
  12.1.2 Dalcetrapib - DalCor Pharmaceuticals
    12.1.2.1 Drug Overview
    12.1.2.2 Mechanism of Action
    12.1.2.3 Clinical Trial Results
    12.1.2.4 Safety and Efficacy
    12.1.2.5 Regulatory Status
  12.1.3 Ticagrelor - AstraZeneca
    12.1.3.1 Drug Overview
    12.1.3.2 Mechanism of Action
    12.1.3.3 Clinical Trial Results
    12.1.3.4 Safety and Efficacy
    12.1.3.5 Regulatory Status
  12.1.4 Evolocumab - Amgen
    12.1.4.1 Drug Overview
    12.1.4.2 Mechanism of Action
    12.1.4.3 Clinical Trial Results
    12.1.4.4 Safety and Efficacy
    12.1.4.5 Regulatory Status
  12.1.5 Ranolazine - Gilead Sciences
    12.1.5.1 Drug Overview
    12.1.5.2 Mechanism of Action
    12.1.5.3 Clinical Trial Results
    12.1.5.4 Safety and Efficacy
    12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ISCHEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ISCHEMIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 ISCHEMIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Ischemia - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Ischemia - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Ischemia - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Ischemia - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Ischemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Ischemia - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Ischemia - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Ischemia - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Ischemia - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Ischemia - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)
    15.5.2.2 Market Forecast by Therapies (2024-2034)
  15.5.3 Ischemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
  15.6.1 Ischemia - Market Size
    15.6.1.1 Market Size (2018-2023)
    15.6.1.2 Market Forecast (2024-2034)
  15.6.2 Ischemia - Market Size by Therapies
    15.6.2.1 Market Size by Therapies (2018-2023)
    15.6.2.2 Market Forecast by Therapies (2024-2034)
  15.6.3 Ischemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
  15.7.1 Ischemia - Market Size
    15.7.1.1 Market Size (2018-2023)
    15.7.1.2 Market Forecast (2024-2034)
  15.7.2 Ischemia - Market Size by Therapies
    15.7.2.1 Market Size by Therapies (2018-2023)
    15.7.2.2 Market Forecast by Therapies (2024-2034)
  15.7.3 Ischemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
  15.8.1 Ischemia - Market Size
    15.8.1.1 Market Size (2018-2023)
    15.8.1.2 Market Forecast (2024-2034)
  15.8.2 Ischemia - Market Size by Therapies
    15.8.2.1 Market Size by Therapies (2018-2023)
    15.8.2.2 Market Forecast by Therapies (2024-2034)
  15.8.3 Ischemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
  15.9.1 Ischemia - Market Size
    15.9.1.1 Market Size (2018-2023)
    15.9.1.2 Market Forecast (2024-2034)
  15.9.2 Ischemia - Market Size by Therapies
    15.9.2.1 Market Size by Therapies (2018-2023)
    15.9.2.2 Market Forecast by Therapies (2024-2034)
  15.9.3 Ischemia - Access and Reimbursement Overview

16 ISCHEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ISCHEMIA MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 ISCHEMIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX


More Publications